Abbreviations: ABCA1 -ATP binding cassette transporter A1; ABCG1 -ATP binding cassette transporter G1; CAD -coronary artery disease; cAMP-cyclic adenosine monophosphate; HDL -high density lipoprotein; LBP -LPS binding protein; LCAT -lecithin-cholesterol acyltransferase; LC-ESI-MS/MS -liquid chromatography electrospray ionization tandem mass spectrometry; LDL -low density lipoprotein; PLTP -phospholipid transfer protein; SAA1/2 -serum amyloid A isoforms 1 and 2 (SAA1.1 and SAA2.1), because SAA1 and SAA2 are highly homologous and not readily distinguishable by proteomics; LXR -liver X receptor; Tukey's HSD -Tukey's honest significant difference. 
Serum amyloid A, efflux capacity and the HDL proteome
INTRODUCTION
Epidemiological and clinical studies have reported a robust, inverse association of HDL cholesterol levels (HDL-C) with risk of coronary artery disease (CAD) (1) . Moreover, mice with genetically engineered deficiencies in proteins involved in HDL metabolism have atherosclerotic phenotypes (2) . These observations provide strong evidence that HDL plays a causal role in vascular disease and have triggered intense interest in targeting HDL for therapeutic intervention.
Several recent observations have cast doubt on the hypotheses that HDL-C levels relate to CAD risk in humans and that elevating HDL-C is therapeutic (3, 4) . For example, genetic variations that alter levels of HDL-C do not always associate with CAD risk, and interventions that elevate HDL-C do not necessarily reduce cardiovascular events in humans with established CAD (5) . Taken together, these observations indicate that HDL is complex and that simply quantifying HDL-C might be a poor way to assess HDL function (6, 7) .
The ability of HDL (or serum HDL, serum depleted of apoB-containing lipoproteins) to promote sterol efflux from cultured macrophages incubated with radiolabeled cholesterol can vary markedly, despite similar levels of HDL-C and apoA-I (8). Therefore, HDL-C is not necessarily the major determinant of HDL's macrophage sterol efflux capacity in this system. Importantly, the efflux capacity of serum HDL is lower in individuals with prevalent CAD (9-11). A recent study of a large cohort initially free of CAD
RESULTS
The human study involved 12 male subjects (40±7 years old: fasting plasma levels of lipids and inflammatory proteins; HDL-C 39.9±3.8 mg/dL, LDL-C 107±4.9 mg/dL, CRP 2.0±0.6 mg/L, SAA 14.3±5.3 μg/mL). All subjects were apparently healthy, normolipidemic, not using medications, and had no symptoms or signs of inflammation. To induce inflammation, subjects were injected with the equivalent of 1 ng/kg (n=8) or 2 ng/kg (n=4) of reference endotoxin (28) . All of the subjects developed the hallmarks of acute inflammation, as indicated by: i) symptoms (chills, headache) and signs (elevated body temperature); ii) a rapid, transient elevation of inflammatory cytokines; and iii) a dose-dependent increase in blood levels of CRP and SAA after the injection (28) .
Acute inflammation induced by low doses of endotoxin remodel the human HDL proteome and impair cholesterol efflux from macrophages. To investigate the ability of HDL and inflammatory HDL to promote sterol efflux from macrophages, we used ultracentrifugation (d=1.063-1.21 g/mL) to isolate HDL from blood collected from each subject 30 min prior to (control HDL) and 24 h after (inflammatory HDL) the injection of saline or low doses of endotoxin. At these doses endotoxin induced only a mild inflammation. The efflux capacity of inflammatory HDL was reduced (Fig. 1A) by ~10% at 1 ng/kg of endotoxin and by ~20% at 2 ng/kg (P=0.009, ANOVA with Tukey's HSD). These observations are consistent with previous reports that the inflammatory response impairs HDL's ability to remove sterol from macrophages in mice, rabbits as well as humans (20-23).
Acute inflammation induced by low doses of endotoxin selectively increases SAA levels in HDL. To assess how changing the relative abundance of proteins in HDL might affect the lipoprotein's function, we analyzed control and inflammatory HDL with mass spectrometry. LC-ESI-MS/MS of tryptic digests of the HDL identified with high confidence (estimated false discovery rate [FDR] 2%) 82 proteins associated with HDL (Supplemental Materials Table S1 ). This approach identified all of the proteins found in our earlier studies of HDL (33, 34) . We also identified number of proteins that were not known to reside in HDL (45) . The fact that we identified more proteins in this analysis than in our previous studies likely reflects improvements in liquid chromatography and mass spectrometers.
To determine which HDL proteins changed in relative abundance when humans were challenged with endotoxin, we used the G-test and t-test to find significant differences in spectral counts, a measure of relative protein abundance (42) . We estimated the FDR by using the same statistical tests with all possible permutations of the data (42) . Permutation analysis revealed that G>3.5 (G-test) and P<0.001 (t-test) yielded the most true-positive changes in protein abundance after endotoxin challenge, with an estimated FDR of 4% (data not shown).
Using these stringent statistical criteria (Fig. 1D, Supplemental Material Table S1 ), the only proteins that changed in relative abundance in inflammatory HDL were the acute-phase proteins SAA1 and SAA2.
The relative concentration of SAA1/2 (SAA1 and SAA2 are quantified together because the proteins share 95% sequence homology) increased 6-fold in the subjects who received the 1 ng/kg dose of endotoxin and 9-fold in those who received the 2 ng/kg dose.
We used two independent approaches to confirm that levels of SAA1 and SAA2 were elevated. First, we used extracted ion chromatograms to quantify the relative abundance of peptides unique to SAA1 and SAA2, because this approach quantifies the individual isoforms and estimates protein ratios more accurately than spectral counting. This approach demonstrated 19-fold and 30-fold increases in ion current for peptides specific for SAA1 (FFGHGAEDSLADQAANEWGR) and SAA2 (GPGGAWAAEVISNAR) in the subjects treated with 1 ng/kg and 2 ng/kg of endotoxin, respectively.
Quantification of SAA with an ELISA (which detects all the SAA isoforms) similarly indicated 15-fold and 17-fold increases of SAA in HDL with 1 and 2 ng/kg of endotoxin. Based on extracted ion chromatograms (Methods), we calculate that SAA represented approximately 13% and 20% of apoA-I with 1 and 2 ng/kg doses of endotoxin, but less than 1% of apoA-I in HDL from the same subjects prior to endotoxin challenge.
To assess how changing the relative abundance of SAA in HDL might affect the lipoprotein's function, we measured the abilities of control HDL and inflammatory HDL to promote cholesterol efflux from by guest, on October 30, 2017 www.jlr.org Downloaded from macrophages (Fig. 1B, C) . There was a strong, inverse linear correlation between HDL sterol efflux ability and levels of SAA in HDL, as assessed by mass spectrometry (r=−0.56, P=0.003) and biochemically (r=−0.64, P=0.001). These observations are consistent with the hypothesis that SAA impairs HDL's ability to promote sterol efflux from macrophages. Because regression analysis indicates that SAA levels only explain approximately 36% of the variance in efflux capacity, other factors also likely contribute to altered efflux capacity including inter-individual differences in sterol efflux capacity without inflammation.
Inflammation with low doses of endotoxin fails to affect plasma lipids in humans. At the time point and low endotoxin doses used in our study, we did not observe significant changes in HDL-C or other plasma lipids (Fig. 1E-G) , the lipid composition of isolated HDL (Fig 1H-J) , or plasma LCAT activity (data not shown). High-resolution size-exclusion chromatography also failed to reveal alterations in the distribution of plasma cholesterol in the endotoxin-treated subjects (data not shown). These observations, in concert with our demonstration of increased levels of SAA1/2 in inflammatory HDL of humans treated with endotoxin, suggest that alterations in the lipoprotein's protein cargo impair its efflux capacity.
SAA1 generates dysfunctional HDL in a model system. To determine whether SAA1 alters sterol efflux from macrophages in vitro, human HDL was first incubated with recombinant SAA1 at various ratios for 3 h at 25°C, and the lipoproteins were then reisolated by ultracentrifugation (d=1.21 g/mL).
SDS-PAGE and densitometric quantification of Imperial Blue-stained proteins ( Fig. 2A,B) indicated that SAA1 accounted for ~10% to 30% of the protein in reisolated HDL -levels markedly higher than those observed with mild inflammation in humans (see above) and similar to that observed in inflammatory HDL from mice (see below). The molar fraction of SAA1 incorporated into HDL increased in concert with the loss of the ability of the lipoprotein to promote sterol efflux from macrophages (Fig. 2C) . ESI-MS/MS of tryptic digests demonstrated that apoA-I and SAA1 were the major proteins that changed in relative abundance when HDL was enriched with SAA1 in vitro (Fig 2D) . These observations support the proposal that SAA enrichment of HDL in vitro impairs its sterol efflux capacity with macrophages.
Acute inflammation alters plasma lipids and remodels the HDL proteome in mice. The human HDL proteome has been extensively investigated (26, 33, 46, 47) , but much less is known about the protein composition of mouse HDL. Previous studies have shown differences in the apoA-I and apoA-II content and apparent sizes of mouse and human HDL (48) . We therefore first characterized the HDL proteome of C57BL/6J mice isolated by ultracentrifugation (d=1.063-1.21 g/mL) and compared it to human HDL. Of the 75 and 82 proteins identified in mouse and human HDL, respectively, 17 were identified only in human HDL, while 8 proteins were detected only in mouse HDL (Supplemental material, Figure S1 ).
Nine of the proteins identified in only mice or human HDL lacked orthologs in the other species.
However, gene ontology analysis of the identified proteins revealed that the HDLs of both species contain the same functional categories of proteins. These data demonstrate that the HDL proteomes of mice and human share many proteins but also are distinct.
To examine the impact of inflammation on the protein cargo of mouse HDL, we injected saline or silver nitrate subcutaneously into wild-type (WT) C57BL/6 mice, and collected blood 24 h later. We used silver nitrate because this model of inflammation, while unsuitable for human studies, has been widely studied in animal models (30, 31) . It also avoids the possibility that any endotoxin adsorbed by HDL would affect cell-based assays. With acute inflammation, HDL isolated from the WT animals exhibited ~20% less efflux capacity in J774 macrophages ( Table S2 ). Peptides for SAA1 and SAA2 were virtually undetectable in HDL of mice injected with saline ( Fig. 3B-D) . In inflamed mice, SAA1 and SAA2 were among the most abundant HDL proteins (Fig. 3E) . Extracted ion chromatograms of peptides specific to each SAA isoform demonstrated marked increase in levels of both SAA1 and SAA2 in inflammatory HDL ( Fig. 3B-D) .
Based on extracted ion chromatograms (Methods), we calculate that SAA1/2 increased from less than 1%
of apoA-I in control HDL to approximately 70% of apoA-I in inflammatory HDL.
With acute inflammation, 18 proteins in HDL increased and 11 decreased in relative abundance (Supplemental Material Table S2 ). Many of those proteins have previously been shown to change in abundance in acute-phase HDL (17, 49), including apoJ, apoE, apoA-V, PLTP, LBP, multiple apoCs, apoM, LCAT, and PON1. Haptoglobin was detected in inflammatory HDL but not control HDL.
Inflammation did not significantly affect levels of the α and β chains of hemoglobin, which have been proposed as markers of dysfunctional HDL (50) . While inflammation induced profound changes in the HDL proteome, it only modestly altered plasma phospholipid and total cholesterol levels ( Fig. 3F,G) . In contrast, inflammation failed to alter HDL-C or HDL particle concentration (Fig 3H,I ).
Acute inflammation does not alter oxidation state of HDL. In addition to altering HDL proteome inflammation may also increase HDL and apoA-I oxidation, a modification known to impair HDL sterol efflux capacity (10, 51-53). We therefore interrogated the proteomics data of WT mice with and without inflammation to determine whether acute inflammation increased oxidation of apoA-I methionine or tryptophan residues (10, 54) . Extracted ion chromatograms of tryptic peptides showed no difference in oxidized peptides containing Met91, Met180 or Trp77 between HDL isolated from control and inflamed mice (data not shown) demonstrating that oxidation is not contributing to impaired sterol efflux of inflammatory HDL.
HDL of inflamed SAA-deficient mice is protected from loss of cholesterol efflux capacity. We next compared the abilities of HDLs isolated from WT and Saa1/2 -/-mice on the same genetic background, without and with inflammation, to promote sterol efflux from macrophages. In the absence of inflammation, there was no difference between the two strains (Fig. 4A) . The efflux capacity of HDL from inflamed WT animals exhibited ~40% loss of efflux capacity compared to HDL of WT animals without inflammation (P<0.001, n=6). In striking contrast, HDL from inflamed Saa1/2 -/-mice exhibited no impairment in the ability to promote sterol efflux (Fig. 4A) Table S3 ). SDS-PAGE of Coomassie-stained proteins indicated that SAA content of HDL of inflamed Saa1/2 -/-mice was markedly reduced (Fig. 4C) ; MS/MS analysis indicated that SAA1/2 was undetectable in these HDLs (see below).
Inflammation-induced alterations in plasma and HDL lipid composition are similar in WT and
Saa1/2 -/-mice. Previous studies demonstrate that inflammation markedly alters the lipid composition of plasma and HDL, and that lipids can contribute to the sterol efflux capacity of HDL by certain pathways (e.g. ABCG1) (49, 55, 56) . We therefore quantified levels of specific lipid classes in plasma and in HDL of WT and Saa1/2 -/-mice, with and without inflammation.
Plasma levels of HDL-C, cholesterol and phospholipids were altered significantly 24 h after injection of silver nitrate (Fig. 4E-G) . However, the patterns of change in plasma lipids and HDL-C during inflammation were similar in WT and Saa1/2 -/-mice ( Fig. 4E-G) . Moreover, there were no significant differences in the inflammation-induced pattern of changes in phospholipid or cholesteryl ester of HDL isolated from WT and Saa1/2 -/-mice (Fig. 4H,I ). The free cholesterol content of HDL increased significantly with inflammation in both strains. The enrichment of HDL from inflamed Saa1/2 -/-mice was significantly greater than that of inflamed WT mice (Fig. 4J) . Together with the data on humans and on HDL enriched in vitro with SAA1, these observations suggest that changes induced by inflammation in the proportions of lipid classes in HDL are unlikely to explain the normal efflux capacity of HDL isolated from inflamed Saa1/2 -/-mice. However, it is possible that inflammation induced alterations in a specific species of lipids (such as phosphatidylserine (57)) contribute to impairment of sterol efflux capacity.
SAA deficiency reduces HDL protein remodeling during inflammation. These observations suggest that increased levels of SAA1/2 and/or lower levels of other HDL proteins might contribute to the loss of efflux capacity of HDL of inflamed WT mice. We therefore compared the protein composition of HDL isolated from WT and Saa1/2 -/-mice, with and without inflammation (Supplemental Material Table   S4 ). In the absence of inflammation, only 2 proteins (SAA4 and APOA2) met our dual statistical criteria for differential protein abundance between HDL isolated from WT and Saa1/2 -/-mice (Supplemental Material, Figure S3 ). In contrast, markedly more proteins differed in relative abundance between control and inflamed WT mice (n=8) than in inflamed Saa1/2 -/-mice (n=8), strongly suggesting that increases in SAA1 and SAA2 remodel the HDL proteome under inflammatory conditions. As expected, SAA1 and SAA2 were undetectable in the inflammatory HDL of Saa1/2 -/-mice (Fig. 4D) .
Loss from HDL of proteins with proposed cardioprotective effects is mediated by SAA. We next compared levels of proposed anti-atherogenic proteins in WT and Saa1/2 -/-mice. The molar fraction of apoA-I, apoE, PLTP and apoA-II were all increased in inflammatory HDL isolated from Saa1/2 -/-mice relative to HDL from WT mice (Fig 4D, inset) Fig S4) . These observations support the proposal that SAA modulates the abundance in HDL of proteins that affect atherosclerosis in mice, and that this in turn may alter the cardioprotective effects of HDL by mechanisms independent of HDL-C.
DISCUSSION
HDL's cardioprotective effect is attributed in part to its ability to mobilize excess cholesterol from artery wall macrophages (2-4, 6, 7). Consistent with this proposal, recent studies demonstrate that impaired sterol efflux capacity of serum HDL from J774 macrophages strongly associates with prevalent and incident CAD status but is independent of HDL-C and apoA-I levels (9, 11, 12). It is therefore critical to uncover the molecular mechanisms that modulate efflux capacity. Because acute inflammation markedly impairs the sterol efflux capacity of HDL in mice and in humans (20-23), we used mass spectrometry to investigate the role of HDL proteins in modulating cholesterol efflux from macrophages. In humans challenged with a low dose of endotoxin (~ 1/2 dose previously published (21)), stringent statistical analysis demonstrated that only two proteins, SAA1 and SAA2, were differentially abundant in inflammatory HDL. Moreover, the ability of HDL isolated from the inflamed subjects to accept cholesterol from macrophages correlated inversely with the HDL's SAA1/2 content. Importantly, inflammation did not significantly change HDL's lipid composition or plasma levels of HDL-C, LDL-C and triglycerides, raising the possibility that the increased SAA1/2 content was the main factor impairing cholesterol efflux from macrophages.
Using WT mice and mice deficient in SAA1/2, we directly determined whether those proteins alter HDL's cholesterol efflux capacity. In the absence of inflammation, the protein composition of HDL isolated from WT mice was essentially identical to that of HDL from the Saa1/2 -/-mice. However, acute inflammation induced with silver nitrate markedly remodeled the HDL proteome of the WT mice. Indeed, the relative abundance of ⅓ of the proteins we detected in WT mouse HDL changed significantly. These observations suggest that the level of inflammation induced by silver nitrate injection in mice was much greater than that we observed in humans treated with low doses of endotoxin. Indeed, we estimate that the relative level of SAA was approximately 70% that of apoA-I in mouse inflammatory HDL compared to ~20% that of apoA-I in inflammatory HDL in humans exposed to the highest dose of endotoxin.
Consistent with previous studies, levels of SAA1/2 were markedly higher in inflammatory HDL of the WT mice, representing ~30% of the protein mass. Moreover, the ability of inflammatory HDL isolated from WT mice to promote sterol efflux from J774 macrophages was markedly impaired, as previously reported by other investigators (21, 22). In contrast, HDL isolated from inflamed Saa1/2 -/-mice was completely protected from the loss of cholesterol efflux capacity. Plasma lipids, HDL-C levels, and HDL lipid composition changed to the same extent in inflamed WT and Saa1/2 -/-mice. Collectively, our observations suggest that SAA enrichment impairs the sterol efflux capacity of HDL in both humans and mice by mechanisms independent of altered lipid composition. However, changes in specific lipid subclasses such as phosphatidylserine might also contribute to impaired sterol efflux capacity during inflammation. In vivo, it is likely that factors other than SAA1/2 associated with inflammation also reduce HDL's ability to inhibit atherogenesis (49, 58, 59 The impact of SAA on sterol efflux capacity is controversial. Early studies showed that lipid-free SAA2
promotes sterol efflux by the ABCA1 pathway (63) . However, virtually all circulating SAA1/2 is associated with HDL in humans and mice (32, 64, 65) , and there is no convincing evidence that free SAA1or SAA2 exists in plasma or blood. A recent study of WT and Saa1/2 -/-mice suggested that SAA does not contribute to impaired reverse cholesterol transport during inflammation in vivo (66) . This study used macrophages containing radiolabeled cholesterol to assess the impact of SAA on HDL function.
Because the radiolabeled macrophages were injected into the animals' peritoneum only 4 h after endotoxin treatment, while circulating SAA levels in HDL generally peak at approximately 24 h after treatment, it is possible that the ability of HDL to promote efflux from macrophages, the initial step of RCT, was not affected by elevated SAA content during the time points used for the study. A recent study of Type 2 diabetics found negative association of SAA levels with SRBI-and no association with ABCG1-mediated cholesterol efflux capacity in 500 diabetic and non-diabetic subjects, although clinical relevance of these assays of sterol efflux capacity is unknown (67) . In contrast, another study suggested that inflammation induced increase in the phospholipid content of HDL modestly improved the ability of HDL to promote sterol efflux by the ABCG1 pathway (55) . However, efflux by this pathway only contributes about 1/4 of the efflux from macrophages to HDL (68 Taken together, our observations provide strong evidence that SAA1 and SAA2 play critical roles in rendering HDL dysfunctional during inflammation (71) .
Recent studies of hypercholesterolemic mice have reached different conclusions regarding the role of SAA in atherosclerosis. ApoE-deficient mice deficient in SAA1/2 fed a Western-type diet were not protected from atherosclerosis (72) . In contrast, a study using lentiviral induced expression of SAA in apoE-deficient mice fed a Western-type diet (73) , as well as a study using adenoviral transfection of SAA in apoE deficient mice on chow diet, found significantly increased atherosclerosis when SAA was expressed (74) .
A key issue then becomes whether the modestly elevated level of SAA found in HDL isolated from hypercholesterolemic animal models of atherosclerosis (75) is likely to affect the efflux capacity of HDL.
Those levels appear to be lower than the levels of SAA1/2 in HDL we observed in our human and mouse studies. The levels of SAA1/2 in humans injected with low doses of endotoxin were significantly lower than those observed in mice injected with silver nitrate (approximately 13 and 20% of apoA-I in HDL in humans compared to 70% in mice), and we observed a more modest impairment of the sterol efflux capacity of inflammatory HDL isolated from humans than mice. Our model system studies also demonstrated that impaired efflux capacity of HDL was quantitatively linked to HDL's content of SAA.
Collectively, these studies indicate that significant levels of SAA in HDL are necessary to cause significant impairment of HDL sterol efflux capacity. Such levels may be relevant in chronic inflammatory diseases associated with elevated risk of cardiovascular disease (e.g. systemic lupus erythematosus, rheumatoid arthritis)(76) or acute coronary syndrome (77) .
Inflammatory HDL that is enriched in SAA1 and SAA2 is also depleted in specific proteins, including several that may be cardioprotective including apoA-I (78). Moreover, we found that levels of PON1 and apoA-II associated with HDL's cholesterol efflux capacity. Collectively, our observations provide strong support for the proposal that SAA alters HDL's biological effects by replacing cardioprotective proteins.
In summary, our observations have identified a specific mechanism-enrichment of the HDL proteome with SAA1/2-that alters HDL's functionality. It is noteworthy that both inflammation and elevated levels of SAA strongly associate with an increased risk of cardiovascular disease in humans (79, 80) . These findings may have important implications for understanding how HDL helps prevent CAD and for developing HDL therapeutics that increase its cardioprotective effects. 
